Kedudukan dalam Saham
#33717
Operating across North America and the Asia-Pacific region, GBS Inc.... Operating across North America and the Asia-Pacific region, GBS Inc. specializes in biosensor diagnostic technology. Its key product is the Saliva Glucose Biosensor, an innovative organic thin-film transistor designed for diabetes management that quantifies glucose levels directly from saliva. The company is also actively advancing a SARS-CoV-2 Biosensor, intended as a supplementary diagnostic tool to existing RNA virus detection tests, and is constructing a broad biosensor platform covering diagnostic modalities such as biochemistry, immunology, tumor markers, hormones, and nucleic acids. GBS Inc. maintains a research agreement with the Johns Hopkins Bloomberg School of Public Health for the development of saliva-based diagnostic solutions. Founded in 2016 and headquartered in New York, New York, the company adopted its current name, GBS Inc., in September 2019, having previously operated as Glucose Biosensor Systems (Greater China) Holdings, Inc. It operates as a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.
Harga Saham
$0.4732
Disegerakkan terakhir: 2022-10-26
Perubahan (1 hari)
-0.03%
Perubahan (1 tahun)
0.00%
Perdagangan GBS Inc. (GBS)
Harga GBS dengan permodalan pasaran b
Modal pasaran bagi GBS Inc.(GBS)
Modal Pasaran: $7.05M
Sehingga August 2026, GBS Inc. mempunyai modal pasaran sebanyak $7.05M. Ini menjadikan GBS Inc. syarikat ke-33717th paling bernilai di dunia mengikut data kami. Kapitalisasi pasaran ialah nilai keseluruhan saham syarikat tersenarai yang berada dalam edaran dan lazimnya digunakan untuk menilai nilai syarikat tersebut.
Sejarah modal pasaran GBS Inc. dari 2020 hingga 2026
GBS berbanding dengan 5 teratas yang paling popular stocks
| Harga GBS |
|
Aset B |
Pasaran B |
Hasilnya |
|
|
|
|
$5.452T
|
+77,373,417.78%
|
|
|
|
|
$4.490T
|
+63,722,769.37%
|
|
|
|
|
$4.162T
|
+59,073,246.83%
|
|
|
|
|
$3.676T
|
+52,174,963.85%
|
|
|
|
|
$2.833T
|
+40,206,758.40%
|
